144 related articles for article (PubMed ID: 37388683)
21. Polyvalent Glycan Functionalized Quantum Nanorods as Mechanistic Probes for Shape-Selective Multivalent Lectin-Glycan Recognition.
Hooper J; Budhadev D; Fernandez Ainaga DL; Hondow N; Zhou D; Guo Y
ACS Appl Nano Mater; 2023 Mar; 6(6):4201-4213. PubMed ID: 37006911
[TBL] [Abstract][Full Text] [Related]
22. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 Omicron (BA.1 and BA.2) specific novel CD8+ and CD4+ T cell epitopes targeting spike protein.
Parn S; Savsani K; Dakshanamurthy S
Immunoinformatics (Amst); 2022 Dec; 8():100020. PubMed ID: 36337685
[TBL] [Abstract][Full Text] [Related]
25. Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies.
Aparicio B; Ruiz M; Casares N; Silva L; Egea J; Pérez P; Albericio G; Esteban M; García-Arriaza J; Lasarte JJ; Sarobe P
Front Immunol; 2022; 13():1044025. PubMed ID: 36761163
[TBL] [Abstract][Full Text] [Related]
26. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
27. Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2.
Swart M; van der Lubbe J; Schmit-Tillemans S; van Huizen E; Verspuij J; Gil AI; Choi Y; Daal C; Perkasa A; de Wilde A; Claassen E; de Jong R; Wiese KE; Cornelissen L; van Es M; van Heerden M; Kourkouta E; Tahiri I; Mulders M; Vreugdenhil J; Feddes-de Boer K; Muchene L; Tolboom J; Dekking L; Juraszek J; Vellinga J; Custers J; Bos R; Schuitemaker H; Wegmann F; Roozendaal R; Kuipers H; Zahn R
NPJ Vaccines; 2023 Mar; 8(1):40. PubMed ID: 36927774
[TBL] [Abstract][Full Text] [Related]
28. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
Guenthoer J; Lilly M; Starr TN; Dadonaite B; Lovendahl KN; Croft JT; Stoddard CI; Chohan V; Ding S; Ruiz F; Kopp MS; Finzi AS; Bloom JD; Chu HY; Lee KK; Overbaugh J
bioRxiv; 2023 Mar; ():. PubMed ID: 36561191
[TBL] [Abstract][Full Text] [Related]
29. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.
Braun MR; Martinez CI; Dora EG; Showalter LJ; Mercedes AR; Tucker SN
Front Immunol; 2023; 14():1086035. PubMed ID: 36911687
[TBL] [Abstract][Full Text] [Related]
30. Man-Specific Lectins from Plants, Fungi, Algae and Cyanobacteria, as Potential Blockers for SARS-CoV, MERS-CoV and SARS-CoV-2 (COVID-19) Coronaviruses: Biomedical Perspectives.
Barre A; Van Damme EJM; Simplicien M; Le Poder S; Klonjkowski B; Benoist H; Peyrade D; Rougé P
Cells; 2021 Jun; 10(7):. PubMed ID: 34203435
[TBL] [Abstract][Full Text] [Related]
31. Legume Lectins with Different Specificities as Potential Glycan Probes for Pathogenic Enveloped Viruses.
Barre A; Van Damme EJM; Klonjkowski B; Simplicien M; Sudor J; Benoist H; Rougé P
Cells; 2022 Jan; 11(3):. PubMed ID: 35159151
[TBL] [Abstract][Full Text] [Related]
32. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
[TBL] [Abstract][Full Text] [Related]
33. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
Lin WS; Chen IC; Chen HC; Lee YC; Wu SC
Front Immunol; 2021; 12():795741. PubMed ID: 34925381
[TBL] [Abstract][Full Text] [Related]
34. Mutations in spike protein T cell epitopes of SARS-COV-2 variants: Plausible influence on vaccine efficacy.
Sankaranarayanan S; Mohkhedkar M; Janakiraman V
Biochim Biophys Acta Mol Basis Dis; 2022 Sep; 1868(9):166432. PubMed ID: 35568352
[TBL] [Abstract][Full Text] [Related]
35. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
36. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
[TBL] [Abstract][Full Text] [Related]
37. Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sites.
Hoffmann D; Mereiter S; Jin Oh Y; Monteil V; Elder E; Zhu R; Canena D; Hain L; Laurent E; Grünwald-Gruber C; Klausberger M; Jonsson G; Kellner MJ; Novatchkova M; Ticevic M; Chabloz A; Wirnsberger G; Hagelkruys A; Altmann F; Mach L; Stadlmann J; Oostenbrink C; Mirazimi A; Hinterdorfer P; Penninger JM
EMBO J; 2021 Oct; 40(19):e108375. PubMed ID: 34375000
[TBL] [Abstract][Full Text] [Related]
38. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
Zhu Y; Hu Y; Liu N; Chong H; He Y
Antiviral Res; 2022 Dec; 208():105445. PubMed ID: 36265805
[TBL] [Abstract][Full Text] [Related]
39. Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation.
Beirag N; Kumar C; Madan T; Shamji MH; Bulla R; Mitchell D; Murugaiah V; Neto MM; Temperton N; Idicula-Thomas S; Varghese PM; Kishore U
Front Immunol; 2022; 13():960733. PubMed ID: 35967323
[TBL] [Abstract][Full Text] [Related]
40. Quantitative profiling of N-glycosylation of SARS-CoV-2 spike protein variants.
Xie Y; Butler M
Glycobiology; 2023 Apr; 33(3):188-202. PubMed ID: 36723867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
